In animal studies, compounds and molecules that disrupt the mechanisms of NLRP3 inflammasome and TLR4 activation have been shown to decrease the production of these mediators, thereby attenuating renal damage caused by hyperuricaemia. The gene discussed is NLRP3; the disease is hyperuricemia.